Luc St-Onge
Corporate Officer/Principal chez Licensing Executives Society
Profil
Luc St-Onge is a Member of Licensing Executives Society and Pharma-Lizenz-Club Deutschland.
He previously worked as Director-Diabetes Program at DeveloGen AG, Chief Business Officer at Affectis Pharmaceuticals AG, and Research Scientist at Max Planck Gesellschaft zur Förderung der Wissenschaften eV.
He holds a doctorate degree from the University of Sherbrooke.
Postes actifs de Luc St-Onge
| Sociétés | Poste | Début |
|---|---|---|
| Licensing Executives Society | Corporate Officer/Principal | - |
| Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Anciens postes connus de Luc St-Onge
| Sociétés | Poste | Fin |
|---|---|---|
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
 Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Corporate Officer/Principal | - |
Affectis Pharmaceuticals AG
 Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Corporate Officer/Principal | - |
Formation de Luc St-Onge
| University of Sherbrooke | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Health Technology |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
| Licensing Executives Society | |
| Pharma-Lizenz-Club Deutschland | |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Miscellaneous |